Format

Send to

Choose Destination
Int J Mol Sci. 2018 Aug 17;19(8). pii: E2431. doi: 10.3390/ijms19082431.

Patient-Derived Xenograft Models for Endometrial Cancer Research.

Author information

1
Pathological Oncology Group, Biomedical Research Institute of Lleida (IRBLLEIDA), University Hospital Arnau de Vilanova, 25198 Lleida, Spain. cmoiola@irblleida.cat.
2
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. cmoiola@irblleida.cat.
3
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. carlos.lopez@vhir.org.
4
Gynecological Oncology Department, Vall Hebron University Hospital, 08035 Barcelona, Spain. scabrera@vhebron.net.
5
Pathology Department, Vall Hebron University Hospital, 08035 Barcelona, Spain. angarcia@vhebron.net.
6
Department of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, Belgium. tom.vannyen@kuleuven.be.
7
Department of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, Belgium. daniela.annibali@kuleuven.be.
8
Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway. Tina.Fonnes@uib.no.
9
Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, CIBERONC, L'Hospitalet del Llobregat, 08907 Barcelona, Spain. avidal@bellvitgehospital.cat.
10
Xenopat S.L, Business Bioincubator, Bellvitge Health Science Campus, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. avidal@bellvitgehospital.cat.
11
Xenopat S.L, Business Bioincubator, Bellvitge Health Science Campus, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. avillanueva@iconcologia.net.
12
Chemoresistance and Predictive Factors Laboratory, ProCURE, Catalan Institute of Oncology (ICO), Oncobell, IDIBELL, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. avillanueva@iconcologia.net.
13
Pathological Oncology Group and Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, 25198 Lleida, Spain. fjmatiasguiu.lleida.ics@gencat.cat.
14
University Hospital Bellvitge, IRBLLEIDA, IDIBELL, CIBERONC, 08907 Barcelona, Spain. fjmatiasguiu.lleida.ics@gencat.cat.
15
Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway. camilla.krakstad@med.uib.no.
16
Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI) and University Medical Centra (UMC), 1066 CX Amsterdam, The Netherlands. frederic.amant@uzleuven.be.
17
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. agil@vhebron.net.
18
Gynecological Oncology Department, Vall Hebron University Hospital, 08035 Barcelona, Spain. agil@vhebron.net.
19
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. eva.colas@vhir.org.

Abstract

Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.

KEYWORDS:

avatar; murine models; orthoxenograft; personalized medicine; preclinical studies; targeted therapy; translational research; uterine cancer

PMID:
30126113
PMCID:
PMC6121639
DOI:
10.3390/ijms19082431
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center